Human muscle precursor cell (hMPC) transplantation is a potential therapy for severe muscle trauma or myopathies. Some previous studies demonstrated that 1,25-dihydroxyvitamin-D 3 (1,25-D 3 ) acted directly on myoblasts, regulating their proliferation and fusion. 1,25-D 3 is also involved in apoptosis modulation of other cell types and may thus contribute to protect the transplanted hMPCs. We have therefore investigated whether 1,25-D 3 could improve the hMPC graft success. The 1,25-D 3 effects on hMPC proliferation, fusion, and survival were initially monitored in vitro. hMPCs were also grafted in the tibialis anterior of SCID mice treated or not with 1,25-D 3 to determine its in vivo effect. Graft success, proliferation, and viability of transplanted hMPCs were evaluated. 1,25-D 3 enhanced proliferation and fusion of hMPCs in vitro and in vivo. However, 1,25-D 3 did not protect hMPCs from various proapoptotic factors (in vitro) or during the early posttransplantation period. 1,25-D 3 enhanced hMPC graft success because the number of muscle fibers expressing human dystrophin was significantly increased in the TA sections of 1,25-D 3 -treated mice (166.75 ± 20.64) compared to the control mice (97.5 ± 16.58). This result could be partly attributed to the improvement of the proliferation and differentiation of hMPCs in the presence of 1,25-D 3 . Thus, 1,25-D 3 administration could improve the clinical potential of hMPC transplantation currently developed for muscle trauma or myopathies.
INTRODUCTION
and/or fusion with host fibers may be a promising strategy to improve hMPC transplantation success (37, 49) . It has been demonstrated that basic fibroblast growth Human muscle precursor cell (hMPC) transplantation is a promising clinical strategy to repair severe muscle factor (bFGF) or insulin-like growth factor type I (IGF-I) modulated the differentiation or the proliferation of injuries (32) , prevent cardiac insufficiency (53,56), and delay the problems of inherited myopathies (50). Briefly, MPCs (2) . Moreover, some studies reported that IGF-I and/or bFGF improved MPC graft success (16, 35) . hMPC transplantation consists of injecting in host muscle hMPCs harvested from a healthy donor or from the However, bFGF stimulated MPC proliferation but depressed their differentiation. In contrast, IGF-I demon-host himself. In the case of hereditary myopathies, the hMPC transplantation permits genetic complementation strated a pronounced stimulation of differentiation but only stimulated proliferation to a small extent (2, 16) . (as a vehicle of normal genes) (49) . As an example, in Duchenne muscular dystrophy (DMD) patients, donor
Although the combination of these two factors produced encouraging results for hMPC transplantation (2, 16) , it hMPCs fused with damaged host muscle fibers introduce their nuclei containing the normal dystrophin gene is still of interest to find other agents improving hMPC proliferation and fusion. and thus restored dystrophin expression (17, 50) . However, the graft success is limited due to an important Classically, the hormonally active vitamin D 3 , 1,25αdihydroxyvitamin D 3 (1,25-D 3 ) interacts with its receptor death of cells (70%) following their injection (49) . It is well established that following a muscle injury, the [vitamin D receptor (VDR)] to induce or repress the expression of a variety of genes (36, 57) , and thereby carry muscular regeneration relies on the proliferation and the differentiation of muscle precursor cells (MPCs) (25) . out many of the physiological actions of vitamin D. In addition, 1,25-D 3 induces nontranscriptional responses Thus, improvement of transplanted hMPC proliferation involving activation of transmembrane signal transduc-ethanol as in the 1,25-D 3 culture medium was added to all the control culture media. tion pathways via a putative novel membrane receptor. Conversely, the VDR might also participate in hormone-Fusion Assay induced nongenomic responses (12, 23) . Thus, it has been demonstrated that 1,25-D 3 , via a modulation of This method has been described previously by Lafreniere et al. (37) . Briefly, the hMPC differentiation protein tyrosine phosphorylation, stimulates proliferation of skeletal muscle myoblasts and promotes their dif-was evaluated by determining a fusion index, which represents the percentage of nuclei included in myotubes ferentiation in myotubes (4, 9, 11, 12, 23, 24) . Furthermore, the presence of VDR has been previously detected in (i.e., cells with at least than three nuclei). To measure this fusion rate of the hMPCs in the presence of 1,25-human skeletal muscle cells and tissues (7, 8, 26, 27) . Thus, 1,25-D 3 could also have proliferative and differ-D 3 , 1 × 10 5 cells were plated in 3timex6-well Costar plates When 50-60% confluence was reached, the cells entiative effects on hMPCs.
Additionally, 1,25-D 3 is commonly known to be in-were rinsed with HBSS and incubated in a differentiation medium (serum-free culture medium completed volved in regulation of cell apoptosis (12, 44) . Interestingly, a significant inflammatory process, involving pro-with 10 µg/ml insulin), which contained or not pharmacological (1 × 10 −6 M) or physiological (1 × 10 −8 M) inflammatory cytokines and oxidative stress, is associated with hMPC transplantation. This inflammatory environ-1,25-D 3 concentrations (44). The differentiation medium was changed every 48 h, and cells were fixed after 4.5 ment plays a crucial role in the early death of donor hMPCs (47). days using 4% paraformaldehyde 0.01 M phosphate buffer. Fixed cell nuclei were stained with DAPI (4′,6-The goal of the present study was to determine whether 1,25-D 3 promotes hMPC transplantation suc-diamidino-2-phenylindole) and observed with a UV lamp microscope using the appropriate filter (magnifica-cess in the tibilalis anterior (TA) of SCID mice. We have investigated whether 1,25-D 3 increased hMPC pro-tion ×10). At the same time, myotubes were identified with standard light microscopy (magnification ×10). liferation and differentiation in vitro and protected them from cell death induced by cytokines and oxidative Three pictures were taken for each well with both microscopy methods. Approximately 800 nuclei were man-stress after the in vivo transplantation. Finally, hMPC transplantation success was increased in SCID mice ually counted per picture (18 pictures per group). treated with 1,25-D 3 . Proliferation, differentiation, and
In Vitro Proliferation Assay viability of transplanted hMPCs were analyzed to understand the mechanisms that could be involved in this ob-To measure the effect of 1,25-D 3 on hMPC proliferation rate, 50,000 cells/well were initially plated in six-served enhancement of graft success.
well plates (Corning Inc., MA, USA). After a 24-h incubation, the antibiotic-free culture medium was added MATERIALS AND METHODS with or without 1 × 10 −6 or 1 × 10 −8 M 1,25-D 3 . Media Human Muscle Precursor Cell (hMPC) Culture were changed 48 h later. To determine cell population, six wells were harvested and separately counted with a hMPCs were obtained from a postmortem biopsy of a 13-month-old boy (33). Briefly, myogenic cells were hematocytometer for each time point (0, 48, 96 h). released from minced fragments by enzymatic dissocia-In Vitro Cellular Mortality Assay tion. After 1 h of incubation in collagenase (600 IU/ml; Sigma-Aldrich, St. Louis, MO, USA), cells were then Several concentrations of staurosporin, TNF-α (Sigma), and glucose oxydase (Gox) (Sigma) were tested incubated for 30 min in Hank's buffer salt solution (HBSS) including 0.1% trypsin and 0.02% EDTA (w/v, in preliminary experiments to induce the highest cell mortality (apoptosis + necrosis). The concentrations and Gibco). hMPCs were cultured in modified MCDB120 medium (Hyclone, Logan, UT, USA) complemented the durations used to induce cell death were as follows: staurosporin (2 µM during 16 h), TNF-α (30 ng/ml dur-with 10% fetal bovine serum (FBS, Invitrogen, Burlington, Ontario, Canada), 10 ng/ml of basic fibroblast ing 24 h), and Gox (0.1 U/ml during 24 h) (13). hMPCs were cultured during 48 h (5% CO 2 , 37°C) growth factor (Strathmann Biotec AG, Hamburg, Germany), 100 U/ml of penicillin, and 100 µg/ml of strepto-in T25 flasks (Corning, Plaza Corning, NY, USA) containing complete culture medium in presence or not of a mycin (Invitrogen). Cells were always kept below 80% confluence.
pharmacological concentration of 1,25-D 3 (1 × 10 −6 M). Following 1,25-D 3 pretreatment, cells were harvested, For all the in vitro experiences, the 1,25-D 3 (17936, Sigma) was reconstituted (1 mg/ml) in ethanol. This washed with HBSS (Sigma), and plated at 1.5 × 10 6 cells/flask with fresh complete medium containing either stock of solution was then diluted in culture media to obtain the concentration required. in female SCID mice treated or not with 1,25-D 3 . Three control mice and three 1,25-D 3 -treated mice were sacri-MO, USA) labeling method described by Shah et al (46) . ficed for each time point (T0, T48, T72, T96 h). Both Animals and Conditioning grafted TAs were harvested at the indicated time points Female SCID mice, 6-8 weeks old (Charles River and snap-frozen in liquid nitrogen. The muscles were laboratory International, Wilmington, MA, USA), were harvested and the DNA was extracted using the Qiagen used as hosts for the transplantation of hMPCs. 1,25-D 3 DNA minikit (Qiagen, Mississauga, Ontario, Canada). (Sigma) was dissolved in ethanol 100% (1 mg/ml) and
Quantification of Cell Death Using Radioactive Lathen diluted in corn oil.
beling. To measure the rapid cell death following trans-Twelve mice were administrated 1,25-D 3 orally (5 plantation, the amount of radioactivity was measured on µg/kg, PO three times per week), from day −7 to day 30 the DNA extracts using a liquid scintillation counter relative to the time of hMPC transplantation. This dose (Mod, Wallac 1409, Woodbridge, Ontario, Canada). The of 1,25-D 3 has been selected in conformity with a protopercentage of radioactivity at all time points and condicol reporting a physiological effect in mice, without sign tions was calculated relative to the T0 value. of hypercalcemia (22, 30) . Twelve control mice received Evaluation of MPC Survival and Proliferation. To vehicle only. Six of these control SCID mice and six of evaluate the survival and the proliferation of the transthe 1,25-D 3 -treated mice were injected intraperitoneally planted hMPCs, the presence of human Y-specific DNA with a daily dose of FK506 during a 30-day period postwas determined by real-time PCR (Rotor-gene 3000, transplantation (2.5 mg/kg/day, Fujisawa Pharmaceuti-Sydney, Australia) in the same DNA extracts used to cal Co. ltd, Osaka, Japan). quantify cell death by radioactivity. A standard curve All experiments were conducted in accordance with was obtained by PCR amplification of DNA extracted the Laboratory Animal Care and Use Ethics Committee from 12 female SCID mouse muscles transplanted with of Laval University.
various numbers of human male myoblasts (0.25, 0.5, 1.0, and 2.0 × 10 6 cells, three mice for each cell num-Graft Success Evaluation ber). The standard curve was obtained by analyzing the Mice were injected in both TAs (8-10 sites of injec-SYBRgreen DNA incorporation at 32 cycles (step 1 at tions) with 1 × 10 6 hMPCs suspended in 10 µl of HBSS 94°C during 30 s, step 2 at 57°C during 30 s, and step using a glass micropipette (Drummond Scientific Co., 3 at 72°C during 20 s) using human Y chromosome-Broomall, PA, USA). Mice were sacrificed after 4 specific primers (sense: 5′-CGTCAGACGACCCAT weeks and grafted TAs were harvested. TAs were then GAA-3′ and antisense 5′-CTCGGTGCATGGCCTGTAplaced in a 30% sucrose solution, embedded in OCT 3′). No Y-specific DNA was detected in the DNA ex-(Miles Inc., Elkhart, IN, USA), frozen in liquid nitrogen, tracted of female SCID mouse muscles. The PCR ampliand serially sectioned at 12 µm using a Microm cryostat.
fication results obtained in different hMPC transplanted Cryostat sections were incubated with a mouse antimuscles was compared to the standard curve to deterhuman-dystrophin antibody (Novocastra Laboratories mine the quantity of living cells. Ltd, Newcastle, UK) followed by a goat anti-mouse IgG
The proliferation of transplanted hMPCs was quantibiotin-conjugated (Dakocytomation, Mississauga, Ont., fied by the proliferation index (i.e., the percentage of Y-Canada) and with a streptavidin-Cy3 conjugated (Sigma). specific DNA divided by the mean percentage of radio-Nonspecific binding sites were blocked for all immunolabeled DNA measured in the same DNA extract). The histochemical detections with FBS 10% in PBS. Human mean proliferation index was then calculated for each dystrophin staining was observed with a UV lamp migroup of SCID mice. croscope using the appropriate filter.The number of human dystrophin-positive fibers was determined for each
Statistical Analysis TA section. The mean of the three best sections was Data were expressed as the mean ± SD of each expercalculated. Thus, to evaluate the graft success, the numimental group. Differences among groups were statistiber of human dystrophin-positive fibers was represented cally analyzed using a one-way ANOVA test. A value by the mean obtained for all the TAs of a group.
of p < 0.05 was considered significant.
In Vivo Cellular Mortality and Proliferation Assay RESULTS
In Vitro Fusion Assay Transplantation of Male Radioactively Labeled MPCs. hMPCs were cultured during 48 h before the transplan-A fusion assay was used to evaluate the effect of 1,25-D 3 on hMPC differentiation rate. Cells were cul-tation in MCDB120 containing 0.25 µCi/ml [methyl-tured 5 days in the presence or not of two different con-the physiological dose, 1 × 10 −8 M 1,25-D 3 , the proliferation curve of hMPCs was comparable to the control. The centrations of 1,25-D 3 (1 × 10 −6 or 1 × 10 −8 M). To identify the fused nuclei, light microscopy and DAPI results were also confirmed at 48 h by a fluorescencebased proliferation assay (Cyquant, data not shown). coloration pictures were merged for each experimental condition. The fusion index represents the percentage of
In Vitro Mortality Assay nuclei in myotubes (cells with at least three nuclei). In this experimental context, untreated hMPCs were par-hMPCs were cultured 48 h in the presence or not of 1,25-D 3 (1 × 10 −6 M). The medium was then removed tially differentiated (49.4 ± 1.45%) (Fig. 1) . The fusion index was increased (p < 0.001) for both 1,25-D 3 con-and cells were cultivated 24 h with staurosporin, TNFα, or Gox. Apoptosis was detected by flow cytometry centrations (55.34 ± 1.44% for 1 × 10 −8 M and 61.54 ± 1.7% for 1 × 10 −6 M). Moreover, the fusion index for the using the Hoechst-PI (Fig. 3) . For the different proapoptotic treatments, the mean level of hMPC mortality pharmacological 1,25-D 3 concentration (1 × 10 −6 M) was significantly enhanced compared to the physiological without 1,25-D 3 was important (82.83 ± 0.56% for the staurosporin, 86.29 ± 0.86% for the TNF-α, and84.17 ± 1,25-D 3 concentration (p < 0.001).
0.47% for the Gox). These levels of hMPC mortality In Vitro Proliferation Assay induced by the proapoptotic factors were not significantly decreased in the presence of 1,25-D 3 (87.03 ± To determine whether 1,25-D 3 enhances hMPC proliferation, a basic cell count was performed. hMPCs 1.71% for the staurosporin, 91.24 ± 1.72% for the TNFα, and 83.73 ± 0.56% for the Gox). Thus, hMPCs pre-were incubated in MCDB120 culture medium complemented with 1 × 10 −6 or 1 × 10 −8 M 1,25-D 3 and cell treated with 1,25-D 3 are not protected from cell death induced by different proapoptotic factors. As a positive populations were evaluated at 0, 48, and 96 h. As shown in Figure 2 , the hMPC population doubled in approxi-control, we have done a similar protocol with staurosporin to induce apoptosis and IGF-1 (50 ng/ml) instead mately 35-40 h. Interestingly, the proliferation of hMPCs in presence of 1 × 10 −6 M 1,25-D 3 was enhanced of VD 3 . As described in other studies (38, 39) , a protective effect was observed with the IGF-1 (data not shown). at 48 and 96 h compared to the control (p < 0.001). For 
Graft Success
1,25-D 3 treatment (Fig. 5 ). The FK506 administration to the 1,25-D 3 -treated mice did not alter the graft success SCID mice were transplanted with 1 × 10 6 hMPCs. improvement described above. The mean number of hu-Half of these mice received 1,25-D 3 orally from day −7 man muscle-positive fibers in mice that received both to day 30 relative to the time of hMPC transplantation.
FK506 and 1,25-D 3 remained elevated (166.2 ± 21.2) In addition, half of the 1,25-D 3 -treated or control mice compare to mice that received no drug (103 ± 18.3) or were injected daily with FK506 (as mentioned in Mateonly FK506 (92 ± 14.0). rials and Methods) starting the day of hMPC transplantation. TAs of all mice were harvested 1 month after the In Vivo Mortality and Proliferation graft. An immunohistochemical staining was performed to observe the presence of human dystrophin-positive Radioactively labeled male hMPCs were transplanted in female SCID mice to follow their death and prolifera-fibers resulting from the fusion of the transplanted hMPCs with the host mouse muscle fibers. As shown in tion. Half of these SCID mice transplanted with hMPCs were administered 1,25-D 3 orally (5 µg/kg three times Figure 4A , the mean number of muscle fibers expressing human dystrophin was significantly increased (p < 0.001) per week). TAs were harvested at 0, 48, 72, and 96 h after hMPC transplantation. Radioactivity and the pres-in the TA sections of 1,25-D 3 -treated mice (166.8 ± 20.6), compared to the control mice (97.5 ± 16.6). Rep-ence of hMPC Y-specific DNA within each TA were measured in the same DNA extracts and expressed as resentative pictures of untreated or 1,25-D 3 -treated TA sections are shown in the Figure 4B .
percentages of the T0 value (Fig. 6A , filled and open columns, respectively). The percentage of radioactivity A sustained FK506 immunosuppressive treatment is currently associated with hMPC transplantation to Du-remaining posttransplantation initially dropped rapidly to 30% at 48 h and then decreased more slowly to 7% chenne muscular dystrophy patients to avoid graft rejection (21,51). We have assessed whether this immuno-at 96 h as shown in Figure 6A (filled columns). This loss of radioactivity is due to the death of the trans-suppressive conditioning has adverse effects on the MPC Transplantation Success Is Reduced DNA was always higher than the percentage of radioacby Cell Death tivity (Fig. 6A ) because the loss of male DNA due to cell death was partially compensated by cell prolifera-
The transplantation of hMPCs is a promising treatment to increase the repair of damaged muscles and to tion. For each time point, there was no significant difference in the percentage of radioactivity between the con-delay the severe problems of inherited myopathies. The originality of this approach is that the in vivo prolifera-trol and the 1,25-D 3 -treated mice. Interestingly, at 96 h, the percentage of hMPC Y-specific DNA was signifi-tion of hMPCs, before their fusion, may increase the number of cells able to either fuse later with damaged cantly higher (p < 0.01) in 1,25-D 3 -treated mice (33.25 ± 1.67) than in control mice (26.36 ± 2.26). To determine host muscle fibers or with each others to form neofibers resulting exclusively from the fusion of transplanted the proliferation of viable hMPCs, an index of hMPC proliferation was calculated by dividing the percentage cells (51) . Moreover, recent results obtained by our group indicated that transplanted MPCs are still able to of hMPC Y-specific DNA by the percentage of radioactivity for the same muscle (Fig. 6B) . Interestingly, we participate in the repair of damaged fibers more than 2 weeks after their transplantation (14). Thus, hMPC observed that hMPCs proliferated constantly, in 1,25-D 3 -treated as well as in control mice, because the prolif-transplantation could permit to treat severe muscle injuries. It has been demonstrated in SCID mice that hMPCs eration index increased progressively. Moreover, this proliferation index being around 2 at 48 h after the trans-participated in the muscle regeneration with a high degree of efficacy (33). Furthermore, a recent clinical trial plantation and around 4 at 96 h after the transplantation, the hMPC population doubling time in vivo (48 h) was confirmed that hMPC transplantation could restore dystrophin expression in DMD patients (51, 52) . However, slightly higher than the doubling time observed in vitro (36-40 h in Fig. 2) . Moreover, the proliferation index one of the main problems facing this therapy is the high loss of about 60-70% of the grafted cells in the first 48 in mice treated with 1,25-D 3 was significantly increased h posttransplantation (Fig. 6A ). This observation con-into myotubes (12) , and activation of tyrosine phosphorylation pathways mediates its effects on muscle growth. firms previous results obtained in our laboratory or by other teams (13, 28, 29, 47, 48, 54) . Nevertheless, this im-In proliferating myoblasts, 1,25-D 3 rapidly promotes tyrosine phosphorylation of ERK-1/2, PLCγ (41) . Ras, c-portant drop of viable cells was partially balanced by the proliferation of transplanted cells (48). This result Src, Raf-1, and MAPKK (also known as MEK) participate in the activation of ERK-1/2 by 1,25-D 3 (19, 42) ; was confirmed ( Fig. 6A ) with the partial compensation by cell proliferation of the lost of male DNA due to cell moreover, in muscle cells, the ERK cascade is positively regulated by PKCa through Raf-1 activation (19, 42) , and death. In addition, it has been reported that an enhancement of the MPC fusion could contribute to the im-by Ca2C and calmodulin-dependent protein kinase II at the level of c-Src (19, 42) . Through these mechanisms, provement of the graft success (16, 37) . Therefore, it seems evident that, to promote effectively muscle regen-1,25-D 3 causes translocation of ERK-1/2 from the cytoplasm to the nucleus in an active phosphorylated form eration, hMPCs must encounter an environment that improves their proliferation, fusion, and survival. and induces the synthesis of the growth-related protein c-myc and stimulation of muscle cell proliferation (18) .
1,25-D 3 Signalization Pathways in Skeletal
The signaling pathways involved in the differentiation Muscle Cells of skeletal muscle cells remain to be established. Nevertheless, the relative contribution of ERK-1/2, p38, and There is evidence that MAPK cascades are involved in the regulation of myogenesis (58) . 1,25-D 3 stimulates JNK-1/2 through reorganization of actin cytoskeleton could participate in muscle cell differentiation (20) . the proliferation of myoblasts and their differentiation 
1,25-D 3 Enhanced hMPC Proliferation and Fusion 1,25-D 3 Did Not Reduce Apoptosis
In the present study, we also investigated whether We thus initially investigated the 1,25-D 3 effect on hMPC proliferation and fusion. Several studies demon-1,25-D 3 protects hMPCs during the early posttransplantation period. The mechanisms involved in the early strated that 1,25-D 3 enhanced the proliferation and the differentiation of chicken embryonic myoblasts (9- death of transplanted cells remain unclear (29, 47, 48) . However, some studies demonstrated that the myoblast 11,24,59). In accordance with these results, we observed, that 1 × 10 −6 M 1,25-D 3 clearly enhanced the in graft success could be improved by preserving them from diverse proapoptotic factors (13,28). As observed vitro proliferation of hMPCs (Fig. 2) . Moreover, we demonstrated that 1,25-D 3 improved hMPC fusion rela-in our in vitro experiments (Fig. 3) , hMPCs pretreated with 1,25-D 3 were not protected from cell death induced tive to the untreated control (Fig. 1) . As expected, the in vivo proliferation of grafted hMPCs was similarly in-by different proapoptotic factors such as TNF-α, oxidative stress, or staurosporin. Each of these factors is in-creased, compared to the control group, at 96 h posttransplantation ( Fig. 6A, B) . Thus, we conclude that the volved in diverse apoptotic signaling pathways, which should be participating in vivo in the early death of improvement of hMPC transplantation observed (Fig.  4A, B ) could partially be due to the proliferative effect transplanted cells (13). Thus, as expected from the in vitro experiment (Fig. 3) , 1,25-D 3 administration did not of 1,25-D 3 . The increased hMPC differentiation induced by 1,25-D 3 was also demonstrated in vitro (Fig. 1) . This reduce the death of the cells transplanted in muscles in vivo ( Fig. 6A) . Indeed, a similar drop of the percentage 1,25-D 3 effect could also be responsible in part for the improved graft success. However, it remains presently of hMPC radioactivity was observed in the 1,25-D 3treated and in the control mice. Nevertheless, hMPC difficult to evaluate whether it is the 1,25-D 3 effect on proliferation or on differentiation that plays the most im-graft success was significantly increased in 1,25-D 3treated mice relative to control mice (Fig. 4A, B) . Thus, portant role in the increased graft success.
1,25-D 3 did not improve the success of hMPC transplantation by a reduction of early hMPC death.
Possible Interaction of 1,25-D 3 With the Specific and Innate Immunities
CONCLUSION Several previous studies reported that 1,25-D 3 also
This study demonstrates for the first time that 1,25-D 3 modulates the immune peripheral tolerance (1,5,6,15, increases hMPC proliferation and fusion. This property 30, 31, 43, 45) . SCID mice were thus used in the present was observed in vitro for the fusion and in vitro/in vivo study to exclude the possibility that the improved graft for the proliferation. These proliferative and differentiasuccess involved a modulation of the specific immune tive effects could partially contribute to hMPC transplanresponse.
tation improvement observed in the 1,25-D 3 -treated mice. A significant inflammatory process is associated with
We have also established that 1,25-D 3 treatment does not hMPC transplantation and there are some significant evprotect the grafted hMPCs from the high mortality, which idences concerning the modulation of the innate immuoccurs in the early posttransplantation period. Thus, 1,25nity by 1,25-D 3 (22, 34) . In the early posttransplantation D 3 did not increase the MPC graft success through a period, a high hMPC mortality was observed in control mechanism involving a reduction of early cell death. Furmice as well as in 1,25-D 3 -treated mice (Fig. 6A ). This ther investigations should be done to understand which result suggests that innate immunity modulation by other 1,25-D 3 properties and by which signaling pathways 1,25-D 3 is not involved in the enhanced hMPC graft sucthis vitamin could be involved in the improvement of cess.
hMPC transplantation. Nevertheless, in regard to the re-Clinical trials based on allotransplantation of hMPCs sults obtained in this study, we conclude that 1,25-D 3 or currently used FK506 immunosuppression (51, 52) . its analogs (3) could be good candidates to improve thera-Some studies reported a positive synergy between pies based on hMPC transplantation. FK506 and 1,25-D 3 (40, 55) . As described in Figure 5 
